However, owing to significant progress made in biotechnological sciences, medical treatment of IBD has been greatly improved by the introduction of biological agents capable of targeting pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-12/23, and α4β7 integrin, which are involved in immune responses [2]. The gene discussed is TNF; the disease is inflammatory bowel disease.